FDA grants breakthrough therapy status to GSK's anaemia drug eltrombopag

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for GlaxoSmithKline's (GSK) Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anaemia (SAA) who have had insufficien…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news